TY - JOUR
T1 - Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach
AU - Sundaram, Srinand
AU - Kim, Eun Na
AU - Jones, Georgina M.
AU - Sivagnanam, Shamilene
AU - Tripathi, Monika
AU - Miremadi, Ahmad
AU - Di Pietro, Massimiliano
AU - Coussens, Lisa M.
AU - Fitzgerald, Rebecca C.
AU - Chang, Young Hwan
AU - Zhuang, Lizhe
N1 - Funding Information:
We thank all patients who contributed to the study. We thank Tara Evans, Michele Bianchi, Bincy Alias, and other members of the NIHR Cambridge Clinical Research Centre for their assistance in the collection of the EMR tissues. We thank the Human Research Tissue Bank, which is supported by the UK National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, from Addenbrooke’s Hospital. We acknowledge the infrastructure support from the Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). We thank Dr. Juliane Perner and Dr. Sriganesh Jammula for assistance in initial analysis of cell density and proportion, and critical assessment of the manuscript.
Funding Information:
This work was supported by the CRUK-OHSU joint grant to YC and LZ (C65718/A29808) and was supported in part by the National Cancer Institute - U54CA209988. YC and LC acknowledges funding from the National Institutes of Health (1U01 CA224012, U2C CA233280), the Knight Cancer Institute, and the OHSU-Brenden-Colson Center for Pancreatic Care. The laboratory of RF is funded by a Core Programme Grant from the Medical Research Council (RG84369).
Publisher Copyright:
Copyright © 2022 Sundaram, Kim, Jones, Sivagnanam, Tripathi, Miremadi, Di Pietro, Coussens, Fitzgerald, Chang and Zhuang.
PY - 2022/5/19
Y1 - 2022/5/19
N2 - Esophageal adenocarcinoma (EAC) develops from a chronic inflammatory environment across four stages: intestinal metaplasia, known as Barrett’s esophagus, low- and high-grade dysplasia, and adenocarcinoma. Although the genomic characteristics of this progression have been well defined via large-scale DNA sequencing, the dynamics of various immune cell subsets and their spatial interactions in their tumor microenvironment remain unclear. Here, we applied a sequential multiplex immunohistochemistry (mIHC) platform with computational image analysis pipelines that allow for the detection of 10 biomarkers in one formalin-fixed paraffin-embedded (FFPE) tissue section. Using this platform and quantitative image analytics, we studied changes in the immune landscape during disease progression based on 40 normal and diseased areas from endoscopic mucosal resection specimens of chemotherapy treatment- naïve patients, including normal esophagus, metaplasia, low- and high-grade dysplasia, and adenocarcinoma. The results revealed a steady increase of FOXP3+ T regulatory cells and a CD163+ myelomonocytic cell subset. In parallel to the manual gating strategy applied for cell phenotyping, we also adopted a sparse subspace clustering (SSC) algorithm allowing the automated cell phenotyping of mIHC-based single-cell data. The algorithm successfully identified comparable cell types, along with significantly enriched FOXP3 T regulatory cells and CD163+ myelomonocytic cells as found in manual gating. In addition, SCC identified a new CSF1R+CD1C+ myeloid lineage, which not only was previously unknown in this disease but also increases with advancing disease stages. This study revealed immune dynamics in EAC progression and highlighted the potential application of a new multiplex imaging platform, combined with computational image analysis on routine clinical FFPE sections, to investigate complex immune populations in tumor ecosystems.
AB - Esophageal adenocarcinoma (EAC) develops from a chronic inflammatory environment across four stages: intestinal metaplasia, known as Barrett’s esophagus, low- and high-grade dysplasia, and adenocarcinoma. Although the genomic characteristics of this progression have been well defined via large-scale DNA sequencing, the dynamics of various immune cell subsets and their spatial interactions in their tumor microenvironment remain unclear. Here, we applied a sequential multiplex immunohistochemistry (mIHC) platform with computational image analysis pipelines that allow for the detection of 10 biomarkers in one formalin-fixed paraffin-embedded (FFPE) tissue section. Using this platform and quantitative image analytics, we studied changes in the immune landscape during disease progression based on 40 normal and diseased areas from endoscopic mucosal resection specimens of chemotherapy treatment- naïve patients, including normal esophagus, metaplasia, low- and high-grade dysplasia, and adenocarcinoma. The results revealed a steady increase of FOXP3+ T regulatory cells and a CD163+ myelomonocytic cell subset. In parallel to the manual gating strategy applied for cell phenotyping, we also adopted a sparse subspace clustering (SSC) algorithm allowing the automated cell phenotyping of mIHC-based single-cell data. The algorithm successfully identified comparable cell types, along with significantly enriched FOXP3 T regulatory cells and CD163+ myelomonocytic cells as found in manual gating. In addition, SCC identified a new CSF1R+CD1C+ myeloid lineage, which not only was previously unknown in this disease but also increases with advancing disease stages. This study revealed immune dynamics in EAC progression and highlighted the potential application of a new multiplex imaging platform, combined with computational image analysis on routine clinical FFPE sections, to investigate complex immune populations in tumor ecosystems.
KW - Barrett’s esophagus
KW - esophageal adenocarcinoma
KW - immune complexity
KW - multiplex imaging
KW - sparse subspace clustering
UR - http://www.scopus.com/inward/record.url?scp=85131343083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131343083&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.874255
DO - 10.3389/fimmu.2022.874255
M3 - Article
C2 - 35663986
AN - SCOPUS:85131343083
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 874255
ER -